We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-9.98%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.17B
AUM Growth
-$1.61B
Cap. Flow
-$473M
Cap. Flow %
-7.66%
Top 10 Hldgs %
32.27%
Holding
171
New
12
Increased
33
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$89.7M
2
PFE icon
Pfizer
PFE
+$66.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$65.8M
4
ARGX icon
argenx
ARGX
+$49.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$47.1M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$136M
2
BMY icon
Bristol-Myers Squibb
BMY
+$116M
3
HCA icon
HCA Healthcare
HCA
+$100M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$82.9M
5
SVA
Sinovac Biotech, Ltd
SVA
+$72.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$18.3B
$82.1M 1.33%
875,515
-56,400
-6% -$4.78M
DXCM icon
27
DexCom
DXCM
$29.2B
$76.7M 1.24%
599,600
-12,000
-2% -$1.31M
TMO icon
28
Thermo Fisher Scientific
TMO
$216B
$71.2M 1.16%
120,600
+25,900
+27% +$14.9M
SIBN icon
29
SI-BONE Inc
SIBN
$804M
$70.9M 1.15%
3,139,247
+833,947
+36% +$17.3M
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.88B
$70.2M 1.14%
3,196,876
– –
PRLD icon
31
Prelude Therapeutics
PRLD
$364M
$69.3M 1.12%
10,039,691
– –
NTRA icon
32
Natera
NTRA
$36.4B
$64.9M 1.05%
1,595,385
+181,400
+13% +$10.9M
SRRA
33
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$63M 1.02%
1,964,770
+487,450
+33% +$14M
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
$54.6M 0.89%
+1,576,600
New +$47.1M
TPTX
35
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$54.2M 0.88%
2,018,950
-87,500
-4% -$2.94M
THC icon
36
Tenet Healthcare
THC
$22.3B
$54M 0.88%
628,300
+329,300
+110% +$27.1M
ARGX icon
37
argenx
ARGX
$55.3B
$53.5M 0.87%
+169,800
New +$49.4M
XTNT icon
38
Xtant Medical Holdings
XTNT
$59.1M
$49.6M 0.8%
72,943,918
+70,424
+0.1% +$46.1K
RPTX
39
DELISTED
Repare Therapeutics
RPTX
$47.3M 0.77%
3,322,488
– –
MGTX icon
40
MeiraGTx Holdings
MGTX
$1.08B
$45.7M 0.74%
3,296,666
-430,800
-12% -$6.63M
KNTE
41
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$45.5M 0.74%
4,043,629
+195,700
+5% +$2.15M
EVH icon
42
Evolent Health
EVH
$397M
$45.2M 0.73%
1,400,000
+462,000
+49% +$12.1M
ABCL icon
43
AbCellera Biologics
ABCL
$1.64B
$40.8M 0.66%
4,180,768
– –
JANX icon
44
Janux Therapeutics
JANX
$901M
$40.7M 0.66%
2,836,386
– –
NSTG
45
DELISTED
NanoString Technologies, Inc.
NSTG
$40.2M 0.65%
1,157,387
+350,287
+43% +$12.1M
SNDX icon
46
Syndax Pharmaceuticals
SNDX
$1.68B
$37.5M 0.61%
2,158,300
+177,000
+9% +$2.98M
ALPN
47
DELISTED
Alpine Immune Sciences Inc
ALPN
$36.6M 0.59%
4,081,592
– –
PCVX icon
48
Vaxcyte
PCVX
$7.71B
$36.6M 0.59%
1,513,659
+416,959
+38% +$9.11M
TELA icon
49
TELA Bio
TELA
$30.9M
$35.2M 0.57%
3,027,542
– –
NPCE icon
50
Neuropace
NPCE
$490M
$32.9M 0.53%
4,012,281
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2022 Portfolio in Review

As of Q1 2022, OrbiMed held 171 positions worth $6.17B, down 21% from $7.78B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $473M in Q1 2022, closing 28 positions and reducing 25 holdings. Its most notable exit was Merck, an estimated $136M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, OrbiMed opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $85.3M.

  • OrbiMed's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 719,034 shares worth $85.3M.
  • OrbiMed added most to Pfizer in Q1 2022, an estimated $66.9M increase.
  • OrbiMed's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $116M.
  • OrbiMed fully exited Merck in Q1 2022, selling an estimated $136M.
  • OrbiMed's ten largest holdings make up 32% of its $6.17B portfolio in Q1 2022.
  • OrbiMed opened 12 new positions and closed 28 in Q1 2022.
  • OrbiMed's portfolio value fell 21% quarter-over-quarter to $6.17B.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.